SWP
GANX icon

Stratos Wealth Partners’s Gain Therapeutics GANX Stock Holding History

Stratos Wealth Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Buy
200,000
+68,379
+52% +$126K ﹤0.01% 1246
2026
Q1 		$255K Buy
+131,621
New +$286K ﹤0.01% 1414

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Stratos Wealth Partners's GANX Position: Q2 2026 in Review

Stratos Wealth Partners increased its Gain Therapeutics (GANX) stake by 52% in Q2 2026, buying an estimated $126K and bringing the position to 200,000 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #1246.

Stratos Wealth Partners first reported a position in GANX in Q1 2026 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Stratos Wealth Partners held 200,000 shares of Gain Therapeutics worth $406K as of Q2 2026.
  • Stratos Wealth Partners bought 68,379 Gain Therapeutics shares in Q2 2026, an estimated $126K.
  • Gain Therapeutics made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1246 holding.
  • Stratos Wealth Partners first reported a position in Gain Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.